8ZF logo

Polarean Imaging DB:8ZF Stock Report

Last Price

€0.016

Market Cap

€20.1m

7D

3,100.0%

1Y

-74.4%

Updated

03 Oct, 2024

Data

Company Financials +

8ZF Stock Overview

Operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States.

8ZF fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Polarean Imaging plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Polarean Imaging
Historical stock prices
Current Share PriceUK£0.016
52 Week HighUK£0.12
52 Week LowUK£0.0005
Beta0.37
11 Month Change-17.95%
3 Month Change-17.95%
1 Year Change-74.40%
33 Year Change-97.38%
5 Year Changen/a
Change since IPO-97.93%

Recent News & Updates

Recent updates

Shareholder Returns

8ZFDE Medical EquipmentDE Market
7D3,100.0%1.8%-1.0%
1Y-74.4%6.7%12.8%

Return vs Industry: 8ZF underperformed the German Medical Equipment industry which returned 8.3% over the past year.

Return vs Market: 8ZF underperformed the German Market which returned 13.8% over the past year.

Price Volatility

Is 8ZF's price volatile compared to industry and market?
8ZF volatility
8ZF Average Weekly Movement3,477.1%
Medical Equipment Industry Average Movement5.3%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 8ZF's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8ZF's weekly volatility has increased from 2244% to 3477% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201629Chris Von Jakopolarean.com

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polariser devices in Canada, the United Kingdom, and the United States. It engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. The company also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags.

Polarean Imaging plc Fundamentals Summary

How do Polarean Imaging's earnings and revenue compare to its market cap?
8ZF fundamental statistics
Market cap€20.10m
Earnings (TTM)-€7.75m
Revenue (TTM)€1.69m

11.9x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8ZF income statement (TTM)
RevenueUS$1.87m
Cost of RevenueUS$1.03m
Gross ProfitUS$836.63k
Other ExpensesUS$9.38m
Earnings-US$8.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0071
Gross Margin44.78%
Net Profit Margin-457.39%
Debt/Equity Ratio0%

How did 8ZF perform over the long term?

See historical performance and comparison